EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

The major birch pollen allergen Bet v 1 induces different responses in dendritic cells of birch pollen allergic and healthy individuals



The major birch pollen allergen Bet v 1 induces different responses in dendritic cells of birch pollen allergic and healthy individuals



Plos One 10(1): E0117904-E0117904



Dendritic cells play a fundamental role in shaping the immune response to allergens. The events that lead to allergic sensitization or tolerance induction during the interaction of the major birch pollen allergen Bet v 1 and dendritic cells are not very well studied. Here, we analyzed the uptake of Bet v 1 and the cross-reactive celery allergen Api g 1 by immature monocyte-derived dendritic cells (iMoDCs) of allergic and normal donors. In addition, we characterized the allergen-triggered intracellular signaling and transcriptional events. Uptake kinetics, competitive binding, and internalization pathways of labeled allergens by iMoDCs were visualized by live-cell imaging. Surface-bound IgE was detected by immunofluorescence microscopy and flow cytometry. Allergen- and IgE-induced gene expression of early growth response genes and Th1 and Th2 related cytokines and chemokines were analyzed by real-time PCR. Phosporylation of signaling kinases was analyzed by Western blot. Internalization of Bet v 1 by iMoDCs of both donor groups, likely by receptor-mediated caveolar endocytosis, followed similar kinetics. Bet v 1 outcompeted Api g 1 in cell surface binding and uptake. MoDCs of allergic and healthy donors displayed surface-bound IgE and showed a pronounced upregulation of Th2 cytokine- and NFκB-dependent genes upon non-specific Fcε receptor cross-linking. In contrast to these IgE-mediated responses, Bet v 1-stimulation increased transcript levels of the Th2 cytokines IL-4 and IL-13 but not of NFκB-related genes in MoDCs of BP allergic donors. Cells of healthy donors were either unresponsive or showed elevated mRNA levels of Th1-promoting chemokines. Moreover, Bet v 1 was able to induce Erk1/2 and p38 MAPK activation in BP allergics but only a slight p38 activation in normal donors. In conclusion, our data indicate that Bet v 1 favors the activation of a Th2 program only in DCs of BP allergic individuals.

(PDF same-day service: $19.90)

Accession: 059084753

Download citation: RISBibTeXText

PMID: 25635684

DOI: 10.1371/journal.pone.0117904



Related references

Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. International Archives of Allergy and Immunology 138(1): 59-66, 2005

Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen. Current Opinion in Investigational Drugs 11(5): 586-596, 2010

Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. Journal of Allergy and Clinical Immunology 106(1 Pt 1): 101-109, 2000

Human monoclonal IgG antibodies derived from a patient allergic to birch pollen as tools to study the in situ localization of the major birch pollen allergen, Bet v 1, by immunogold electron microscopy. Journal of Allergy and Clinical Immunology 101(1 Pt 1): 60-66, 1998

Human monoclonal IgG antibodies derived from a patient allergic to birch pollen as tools to study the in situ localization of major birch pollen allergen, Bet v 1, by immunogold electron microscopy. Journal of Allergy & Clinical Immunology 101(1 PART 1): 60-66, 1998

Recombinant derivatives of the major birch pollen allergen Bet v 1, which induce fewer symptoms and lower mediator release and eosinophil activation than rBet v 1 wild-type in nasal challenges in birch pollen allergic patients. Allergy (Copenhagen) 56(Supplement 68): 94, 2001

Bet v 1 and its homologous food allergen Api g 1 stimulate dendritic cells from birch pollen-allergic individuals to induce different Th-cell polarization. Allergy 65(11): 1388-1396, 2011

Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity reactions equal to those induced by natural Bet v 1 in the airways of patients allergic to tree pollen. Journal of Allergy & Clinical Immunology 99(3): 354-359, 1997

Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clinical and Experimental Allergy 34(1): 115-122, 2004

Vaccines for birch pollen allergy based on genetically-engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Allergy (Copenhagen) 56(Supplement 68): 60, 2001

Hypoallergenic recombinant variants of Bet v 1, the major allergen of birch pollen: Tools for specific immunotherapy of birch pollen allergy?. Immunology Letters 56(Part-P1): 219-0, 1997

Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen. Clinical & Experimental Allergy 26(1): 50-60, 1996

In vitro and in vivo characterization of vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Journal of Allergy & Clinical Immunology 107(2): S255, February, 2001

High correlation of specific IgE sensitization between birch pollen, soy and apple allergens indicates pollen-food allergy syndrome among birch pollen allergic patients in northern China. Journal of Zhejiang University. Science. B 17(5): 399-404, 2016

Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. Journal of Allergy and Clinical Immunology 104(5): 969-977, 1999